Ongoing issues in pneumonia care: when to admit, how to treat and the role of oral therapy.
In recent decades the understanding of the diagnosis and treatment of community acquired pneumonia (CAP) has increased within the medical scientific community. The challenge remains how best to disseminate new information to the practicing clinician to facilitate improved outcomes and cost-effective care. To accomplish this end, professional organizations such as the Infectious Disease Society of America (IDSA) and the American Thoracic Society (ATS) have developed and published consensus guidelines reflecting the proposed standard of medical care. Three ongoing areas of ambiguity and divergence between published guidelines and clinical practice include treatment selection, the admission decision, and the utility and role of oral therapy.
Shillington
A C
AC
EPI-Q, Inc., Oakbrook Terrace, Illinois 60181, USA.
D000284:Administration, Oral; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D017714:Community-Acquired Infections / Q000191:economics / Q000628:therapy; D003657:Decision Making; D005260:Female; D006760:Hospitalization; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D017063:Outcome Assessment, Health Care; D010045:Outpatients; D011014:Pneumonia / Q000191:economics / Q000628:therapy*; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D000900:Anti-Bacterial Agents